As the COVID-19 pandemic continues, many sponsors, CROs, investigators, and IRBs have modified clinical trials, moving visits from clinics to living rooms worldwide. When trial participants are children, a more complex decision process must govern when and for whom a move to virtual visits is possible. Dr. Joan Busner at Signant Health looks at the regulatory considerations for child psychiatric trials during COVID-19.